Overview

* Century Therapeutics ( IPSC ) reports Q3 net loss of $34.4 mln, compared to $31.2 mln last year

* R&D expenses decreased to $22.5 mln in Q3, primarily due to reduced personnel costs

Outlook

* Century plans to initiate IND-enabling studies for T1D program by end of 2025

* Company expects to advance CNTY-308 into clinical studies in 2026

* Century estimates cash runway into 4Q 2027

Result Drivers

* COSTS DECLINE - R&D expenses lower primarily due to a reduction of personnel and manufacturing costs, while G&A expenses decrease due to a gain on lease modification

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$34.42

Income mln

Q3 Basic -$0.40

EPS

Q3 $36.12

Operatin mln

g

Expenses

Q3 -$36.12

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Century Therapeutics Inc ( IPSC ) is $6.00, about 90.6% above its November 12 closing price of $0.56

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)